Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sunitinib - Pfizer

Drug Profile

Sunitinib - Pfizer

Alternative Names: PHA-290940; PHA-290940AD; PNU-290940; PNU-290940AD; SU-011248; SU-11248; SU-11428; Sunitinib malate; Sutent

Latest Information Update: 14 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Australasian Sarcoma Study Group; Cancer Research UK; Case Comprehensive Cancer Center; Clatterbridge Cancer Centre NHS Foundation Trust; Hoosier Cancer Research Network; Korean Urological Oncology Society; Memorial Sloan-Kettering Cancer Center; Ohio State University; Pfizer; University of Michigan Comprehensive Cancer Center; University of Texas M. D. Anderson Cancer Center; US Oncology Research
  • Class Amides; Antineoplastics; Ethylamines; Eye disorder therapies; Fluorobenzenes; Indoles; Pyrroles; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Colony stimulating factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastrointestinal stromal tumours; Renal cell carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastrointestinal stromal tumours; Pancreatic cancer; Renal cell carcinoma
  • Phase II Bladder cancer; Neuroendocrine tumours; Oesophageal cancer; Phaeochromocytoma; Prostate cancer; Thyroid cancer; Uveal melanoma
  • Phase I/II Soft tissue sarcoma
  • No development reported Germ cell and embryonal neoplasms; Liver cancer
  • Discontinued Breast cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Urogenital cancer

Most Recent Events

  • 30 Jan 2019 Pfizer and Hoosier Cancer Research Network withdraw the phase II SUAVE trial in Renal cell carcinoma in USA prior to enrolment as the principal investigator leaves the institution and efforts to open the protocol at another institution are not successful (NCT03035630)
  • 02 Jan 2019 Pfizer and the M. D. Anderson Cancer Centre complete a phase II trial for Renal cell carcinoma (Metastatic disease) in USA (NCT02060370)
  • 05 Sep 2018 Discontinued - Phase-II for Urogenital cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in Canada (PO) (Pfizer pipeline, September 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top